Maze Therapeutics to Present Kidney Disease Data at ASN Kidney Week

Maze Therapeutics will present data from its MZE829 and MZE782 programs at ASN Kidney Week 2026. The presentation will include Phase 2 HORIZON data for MZE829 in APOL1-mediated kidney disease patients and preclinical research for MZE782.